A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine
Although treatment options for melanoma patients have expanded in recent years with the approval of immunotherapy and targeted therapy, there is still an unmet need for new treatment options for patients that are ineligible for, or resistant to these therapies. BH3 mimetics, drugs that mimic the act...
Guardat en:
| Autors principals: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2021-07-01
|
| Col·lecció: | Pharmaceuticals |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/1424-8247/14/8/749 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|